

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Hirve, S;Crawford, N;Palekar, R;Zhang, W;Bancej, C;Barr, I;Baumeister, E;Broor, S;Burmaa, A;Campbell, H;Caetano, B;Chadha, M;Chittaganpitch, M;Coulibaly, D;Darmaa, B;Ellis, J;Fahim, M;Fasce, R;Herve, K;Jackson, S;Pisareva, M;Moyes, J;Naguib, A;Nair, H;Pebody, R;Potdar, V;Rajatonirina, S;Siqueira, M;Smith, PG;Smorodintseva, E;Sotomayor, V;Treurnicht, F;Tivane, A;Venter, M;Wairagkar, N;Zambon, M

Title:

Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot

Date:

2020-11-01

Citation:

Hirve, S., Crawford, N., Palekar, R., Zhang, W., Bancej, C., Barr, I., Baumeister, E., Broor, S., Burmaa, A., Campbell, H., Caetano, B., Chadha, M., Chittaganpitch, M., Coulibaly, D., Darmaa, B., Ellis, J., Fahim, M., Fasce, R., Herve, K., ... Zambon, M. (2020). Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot. *Influenza and Other Respiratory Viruses*, 14 (6), pp.647-657. <https://doi.org/10.1111/irv.12688>.

Persistent Link:

<https://hdl.handle.net/11343/252294>

License:

CC BY



ORIGINAL ARTICLE

WILEY

Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot

Siddhivinayak Hirve¹ | Nigel Crawford² | Rakhee Palekar³ | Wenqing Zhang¹ |
on behalf of the WHO RSV surveillance Group

¹Global Influenza Programme, World Health Organization, Geneva, Switzerland

²Royal Children's Hospital, Melbourne, Vic., Australia

³Pan American Health Organization, Washington, DC, USA

Correspondence

Siddhivinayak Hirve, Global Influenza Programme, World Health Organization, Geneva, Switzerland.
Email: hirves@who.int

Funding information

Bill and Melinda Gates Foundation, Grant/Award Number: OPP1127419

Abstract

Background: The lack of a uniform surveillance case definition poses a challenge to characterize the epidemiology, clinical features, and disease burden of the respiratory syncytial virus (RSV). Global standards for RSV surveillance will inform immunization policy when RSV vaccines become available.

Methods: The WHO RSV surveillance pilot leverages the capacities of the Global Influenza Surveillance and Response System (GISRS). Hospitalized and non-hospitalized medically attended patients of any age were tested for RSV using standardized molecular diagnostics throughout the year in fourteen countries. An extended severe acute respiratory infection (extended SARI) or an acute respiratory infection (ARI) case definition was used that did not require fever as a criterion.

Results: Amongst 21 221 patients tested for RSV between January 2017 and September 2018, 15 428 (73%) were hospital admissions. Amongst hospitalized RSV-positive patients, 50% were aged <6 months and 88% <2 years. The percentage of patients testing positive for RSV was 37% in children <6 months and 25% in those aged 6 months to 2 years. Patients with fever were less likely to be RSV positive compared to those without fever (OR 0.74; 95% CI: 0.63-0.86). For infants <6 months, 29% of RSV ARI cases did not have fever.

Conclusion: Requiring fever in a case definition for RSV lowers the sensitivity to detect cases in young children. Countries should consider ways to leverage the GISRS platform to implement RSV surveillance with an augmented case definition amongst the young pediatric population.

KEYWORDS

case definition, respiratory syncytial virus, surveillance

The peer review history for this article is available at <https://publons.com/publon/10.1111/irv.12688>.

Siddhivinayak Hirve and Nigel Crawford equally contributed to this study.

WHO RSV surveillance Group are present in Appendix A.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Influenza and Other Respiratory Viruses* Published by John Wiley & Sons Ltd.

1 | INTRODUCTION

Globally, RSV is the leading infectious cause of respiratory morbidity and mortality in children aged <5 years. Annually, there are an estimated 33 (uncertainty range 21-50) million episodes of RSV-associated acute lower respiratory infection (ALRI), 3.2 (uncertainty range 2.7-3.8) million RSV hospitalizations, and 59 600 (uncertainty range 48 000-74 500) in-hospital RSV deaths.^{1,2} RSV vaccine research and development efforts have progressed significantly in recent years, with some nineteen vaccines and two new generation monoclonal antibody candidates in various stages of clinical trials. It is possible that a maternal RSV vaccine to prevent RSV infection in young infants may be licensed in the next few years.³

Though RSV disease occurs across all ages,⁴⁻⁶ it disproportionately affects children <2 years.⁷ The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has recommended improved case definitions, surveillance, and disease estimates for RSV especially in low- and middle-income countries where the burden is likely to be high.⁸ There is a need for improved RSV surveillance to better understand seasonality and disease burden in different countries.⁹ RSV surveillance is often a by-product of influenza-like illness (ILI) or severe acute respiratory infection (SARI) surveillance.^{10,11} However, these case definitions require a history of fever or measured fever and consequently may miss up to a significant proportion of RSV infections especially in younger children.¹²⁻¹⁴ In 2016, WHO piloted a RSV surveillance strategy that leverages the capacities of the Global Influenza Surveillance and Response System (GISRS) using a broadened case definition.¹⁵ It aimed to establish laboratory and

epidemiological standards for RSV detection to improve the understanding of seasonality, disease burden, and age-groups at highest risk. Using the data collected in this pilot study, this paper aims to describe the clinical predictors for RSV presentation and evaluate the performance of the extended SARI and ARI case definitions for RSV surveillance.

2 | METHODS

Surveillance sites from fourteen countries, from all six WHO regions, participated in the pilot study. Countries were selected based on having a WHO-designated National Influenza Centre and/or a national public health laboratory, a strong national influenza surveillance system and an interest in participation in the pilot. Countries were required to test 1000 patients annually for RSV (250 patients in each of the four age groups—<6 months, 6 months to <5 years, 5 to <65 years, and 65 years and more).

2.1 | Site profile and surveillance practices

In Argentina, Brazil, Chile, Egypt, Russian Federation, and South Africa, patients admitted to sentinel hospitals were screened across all ages, whereas in Australia and Canada pediatric hospital admissions only were screened. In Côte d'Ivoire, India, Mongolia, Mozambique, and Thailand, patients were screened across all ages in both sentinel hospitals and outpatient clinics. In the United Kingdom, patients were screened across all ages attending sentinel

TABLE 1 Sentinel site profile, WHO RSV surveillance, 2017-18

	Age-group under surveillance	Patients under surveillance	# sentinel sites	Start of surveillance	No. tested (% hospitalized)
Argentina	All ages	Inpatient	6	2016 wk52	1214 (99%)
Australia	0-18 y	Inpatient	1	2017 wk31	1560 (100%)
Brazil	All ages	Inpatient	2	2017 wk03	727 (91%)
Canada	0-16 y	Inpatient	12	2017 wk34	2178 ^a (100%)
Chile	All ages	Inpatient	2	2017 wk01	883 (100%)
Côte d'Ivoire	All ages	Inpatient + Outpatient	9	2017 wk01	1772 (36%)
Egypt	All ages	Inpatient	4	2017 wk01	1194 (100%)
India	All ages	Inpatient + Outpatient	11	2017 wk01	1537 (82%)
Mongolia	All ages	Inpatient + Outpatient	7	2017 wk02	1175 (89%)
Mozambique	All ages	Inpatient + Outpatient	4	2017 wk01	969 (76%)
Russian Federation	All ages	Inpatient	18	2016 wk52	1648 (100%)
South Africa	All ages	Inpatient	5	2017 wk01	3409 (100%)
Thailand	All ages	Inpatient + Outpatient	11	2017 wk01	2752 (53%)
United Kingdom ^b	Pediatric	Inpatient	6	2017 wk39	2381 ^c (0%)
	All ages	Outpatient	70 GPs		

Abbreviations: GP, general practitioners; wk, weeks; y, years.

^aCanada has reported data for laboratory-confirmed RSV-positive cases only from 11 of its 12 sentinel sites.

^bSurveillance is restricted to England only.

^cThe United Kingdom has reported case-based data for outpatient surveillance only.

General Practitioner clinics, as well as children under 5 years in sentinel hospitals in England (Table 1). Canada reported data only for those patients who tested RSV positive and was excluded from the analysis. The number and type of sentinel hospitals (secondary and tertiary-level care) varied across countries. The selection of sentinel hospitals and clinics was largely based on patient load and convenience, and there was no requirement for them to be nationally representative.

Physicians and nurses screened patients admitted the previous day with acute onset cough or shortness of breath or, for patients attending outpatient clinics, with at least one of cough, sore throat, shortness of breath, or runny nose. Sepsis and apnea were also criteria for enrollment in infants <6 months (Table 2). Additionally, information on fever, wheeze, and associated risk factors, such as prematurity, malnutrition, cardiac and respiratory illness, and immunodeficiency, were recorded on a standardized case record form. The sampling strategy varied and ranged from screening of all eligible patients to screening a sample of eligible patients (eg, on certain days of the week). Patients were screened all year-round except in Canada and England where patients were screened between November and June. Age-appropriate nasal, nasopharyngeal, or lower respiratory tract specimens were collected and transported in virus transport media for laboratory RSV testing.¹⁶ Specimens from patients with reported or measured fever were additionally tested for influenza and subtyped using standardized rRT-PCR assays.¹⁷

2.2 | Laboratory testing

All laboratories participated in an external quality assurance program using proficiency panels developed by the Division of Viral Diseases at the US Centers for Disease Control and Prevention (CDC), consisting of contemporary and historical strains of RSV-A and RSV-B or

panels supplied by Quality Control for Molecular Diagnostics (QCMD), United Kingdom. Specimens received by laboratories were stored at -70°C and batch tested using a standardized rRT-PCR assay developed by CDC for generic RSV detection. The CDC molecular assay was compatible with a wide range of virus transport media and different extraction systems and PCR amplification platforms. Primers and probes were supplied by CDC, and extraction reagent kits and amplification enzymes were supplied by International Reagent Resource (IRR) of CDC. National laboratories had the option to use commercial or in-house laboratory developed tests (LDTs) provided these were validated against the CDC RSV assay. The US CDC, Public Health England, Colindale, and National Institute of Communicable Diseases, Johannesburg provided training and quality assurance support, as required, to all participating national laboratories. The WHO FluMart data platform was adapted to receive case-based clinical and laboratory RSV data, and countries were required to upload anonymized RSV surveillance data every week or every fortnight. Public access to an interactive aggregated RSV surveillance output was provided at http://ais.paho.org/hip/viz/ed_who_rsv.asp.

2.3 | Data analysis

Data from Canada were excluded for analysis as they had reported only on RSV-positive cases. The start of surveillance varied (range epidemiological week (EW) 52 of 2016 to EW 39 of 2017) with 11 of 14 countries initiating surveillance in the first quarter of 2017. The end date for this analysis was set at EW 39 of 2018. England reported data only from their General Practitioner sentinel surveillance (Table 1). All analyses were done separately for inpatient and outpatient surveillance and disaggregated into six age-groups—<6 months, 6 months to <2 years, 2 to <5 years, 5 to <18 years, 18 to <65 years, and 65 years and more. Univariate

TABLE 2 Surveillance case definitions for RSV, 2017-18

	RSV	Influenza
In patient	Extended SARI <ul style="list-style-type: none"> • Severe (overnight hospitalization) • Acute (onset within past 10 d) • Respiratory infection (cough or shortness of breath) In infants <6 mo age <ul style="list-style-type: none"> • Apnea^a • Sepsis <ul style="list-style-type: none"> • Fever more than 37.5°C or hypothermia • Shock^b • Seriously ill without apparent cause 	SARI <ul style="list-style-type: none"> • Severe (overnight hospitalization) • Acute (onset within past 10 d) • History of fever or measured fever of 38°C or more • Respiratory infection (cough or shortness of breath)
Out patient	ARI <ul style="list-style-type: none"> • Acute (onset within past 10 d) • Respiratory infection (at least one of cough, sore throat, shortness of breath or runny nose) Extended ILI <ul style="list-style-type: none"> • Acute (onset within past 10 d) • Respiratory infection (cough) 	ILI <ul style="list-style-type: none"> • Onset within past 10 d • Measured fever of 38°C or more, and • Cough

Abbreviations: ARI, acute respiratory infection; ILI, influenza-like illness; RSV, respiratory syncytial virus; SARI, severe acute respiratory infection.

^aApnea defined as temporary cessation of breathing from any cause.

^bShock defined as lethargy, fast breathing, cold skin, prolonged capillary refill or weak pulse.




FIGURE 1 Age distribution of specimens tested, WHO RSV surveillance, 2017-18

logistic regression was used to determine clinical predictors for RSV cases. The SARI and ILI case definitions were evaluated against the extended SARI and ARI definitions that did not require fever. The relative sensitivity was estimated as it was not known how many RSV cases were missed who did not fit the extended SARI or ARI case definitions. The positive predictive value (PPV) was calculated for the age-specific percent positivity cumulated over the study period. We also evaluated the individual performance of apnea and sepsis (for infants <6 months), and when wheezing (clinical presentation of RSV-associated bronchiolitis) was added to the extended SARI case definition. The area under the curve (AUC) was estimated as a measure of accuracy of how well an alternate case definition separates the group being tested into those with and without the disease as determined by the existing reference case definition. An AUC (range 0-1) <0.7 indicates a poor discriminatory ability of the alternate case definition in relation to the reference case definition. All analysis was done with Stata v15 software.

3 | RESULTS

A total of 21 221 patients (excluding Canada) were tested for RSV of whom 15 428 (73%) were inpatients (Table 1). Overall, 60% of patients tested were aged <5 years (20% <6 months, 30% between 6 months to 2 years and 10% between 2 and 5 years). The age distribution of patients tested varied by country (Figure 1). Overall, <10% of patients tested were aged 65 years or older (Table 3). Amongst inpatients, a total of 2963 (19.2%) tested positive for RSV. Amongst RSV-positive hospitalized patients, 2598 (87.6%) were <2 years age, and 1461 (49.3%) were <6 months. The percentage testing positive for RSV was similar in males and females.

3.1 | Clinical characteristics

Amongst hospitalized patients, RSV percent positivity was highest (37%) in infants <6 months, 25% in children 6 months to


2 years, and 12% in children 2-5 years age. RSV percent positivity was about 4% in adults and older adults aged 65 years and more. RSV percent positivity was lower but showed similar age trends amongst non-hospitalized patients. In contrast, percent positivity for influenza amongst hospitalized patients was 3%-7% in children <2 years, 11% in adults aged 18 to <65 years, and 14% in older adults aged over 65 years (Figure 2). The age-group stratified RSV percent positivity varied across countries. RSV predominated over influenza in children <2 years age (especially infants <6 months) whereas the reverse was seen in older adults aged 65 years and more. This trend was seen for both hospitalized and non-hospitalized patients across all the participating countries (Figure 3).

Amongst hospitalized patients <6 months, apnea was significantly more prevalent amongst RSV-positive infants (8.3%) than those who tested negative (6.0%) (odds ratio (OR) 1.42; 95% CI: 1.05-1.94) (Table 4). Sepsis was less common amongst RSV-positive infants (4.7%) than those who tested negative (10%) (OR - 0.44; 95% CI: 0.31-0.64). Cough (OR: 6.21, 95% CI: 4.77-8.08), shortness of breath (OR: 1.64, 95% CI: 1.38-1.96), wheezing (OR: 1.73, 95% CI: 1.49-2.01), runny nose (OR: 1.75, 95% CI: 1.50-2.04), and lower chest in-drawing (OR: 2.46, 95% CI: 2.07-2.91) were all significantly more common in RSV-infected infants. The findings were similar for hospitalized children aged 6 months to 2 years, though the association with wheeze was not significant.

The presence of either reported or measured fever was significantly less likely amongst RSV cases than RSV-negative children <2 years than in those aged 6 months to 2 years. Similar trends in clinical predictors were seen in older children, adults, and older adults but were generally not statistically significant. Presence of a pre-existing illness was not significantly associated with RSV infection except in children aged 5-18 years. Clear statistically significant trends for RSV infection for most clinical predictors could not be ascertained for patients for any of the age-groups attending outpatient clinics in a primary care setting, but these analyses were based on smaller numbers of patients and the confidence intervals on odds ratio estimates were generally wide.

TABLE 3 Age, sex distribution of patients, and RSV detection, 2017-18

Age	Inpatient surveillance			Outpatient surveillance		
	RSV negative n (%)	RSV positive n (%)	Tested n (%)	RSV negative n (%)	RSV positive n (%)	Tested n (%)
0 to <6 m	2493 (20.5)	1461 (49.3)	3954 (26.2)	157 (3.3)	40 (9.9)	197 (3.9)
6 m to <2 y	3456 (28.5)	1137 (38.3)	4593 (30.4)	726 (15.6)	157 (38.9)	883 (17.5)
2 to <5 y	1365 (11.2)	187 (6.3)	1552 (10.3)	579 (12.5)	93 (23.0)	672 (13.3)
5 to <18 y	1077 (8.8)	49 (1.6)	1126 (7.4)	768 (16.6)	19 (4.7)	787 (15.6)
18 to <65 y	2546 (21.0)	74 (2.5)	2620 (17.3)	1991 (43.0)	74 (18.8)	2065 (41.0)
65+ y	1175 (9.7)	55 (1.8)	1230 (8.1)	405 (8.7)	20 (4.9)	425 (8.4)
Male	6255 (53.3)	1565 (53.9)	7820 (53.4)	1241 (52.7)	160 (57.5)	1401 (53.2)

FIGURE 2 Age distribution and percent positivity of RSV and influenza, 2017-18

3.2 | Case definition

Amongst hospitalized infants <6 months age, 29% of those RSV cases that otherwise had been captured by an extended SARI case definition were missed after inclusion of measured or reported fever. The positive predictive value (PPV) of the SARI case definition that included fever was 34% for infants <6 months and 24% for children between 6 months to <2 years. The ability of fever to correctly identify the presence or absence of RSV infection was poor (area under the curve (AUC) – 0.31). The percent of missed cases was lower (18-20%) in children 6 months to <5 years age. Apnea and sepsis individually had low sensitivity (8.3% and 4.7%) but were highly specific (93% and 89%) for RSV infection in infants <6 months. The addition of wheeze to the extended SARI case definition reduced the sensitivity to 36% in hospitalized infants <6 months age and to about 32-33% in children aged 6 months to 5 years. Similar trends were seen amongst non-hospitalized children, albeit with lower certainty. Amongst hospitalized older adults aged 65 years and more, the sensitivity of the SARI case definition after inclusion of fever

and wheeze was 78% and 40%, respectively. Amongst non-hospitalized older adults aged 65 years and more, the addition of fever reduced the sensitivity to 27%. However, the addition of wheeze to the extended SARI case definition increased the sensitivity to 98%, respectively (Table 5).

4 | DISCUSSION

The lack of a global uniform surveillance case definition for RSV complicates the interpretation of surveillance data. In the WHO RSV surveillance pilot, the use of an extended SARI or an ARI case definition substantially increased the number of RSV infections detected also seen in other studies.^{12,13} These definitions do not require fever to identify a suspect case. On the other hand, the inclusion of fever in the RSV surveillance case definition may not matter if the objective is solely to ascertain onset of the RSV season. However, including fever may significantly compromise the use of surveillance data to estimate RSV disease burden.




FIGURE 3 A, RSV and influenza proportion positive (inpatient surveillance), 2017-18. B, RSV and influenza proportion positive (outpatient surveillance), 2017-18

TABLE 4 Clinical predictors for laboratory-confirmed RSV for patients with extended SARI and ARI case definition, 2017-18

	Inpatient surveillance			Outpatient surveillance		
	RSV negative n (%)	RSV positive n (%)	Univariate Odds ratio (95% CI)	RSV negative n (%)	RSV positive n (%)	Univariate Odds ratio (95% CI)
Young infants (0 to <6 m)						
Apnea	103 (6.0)	75 (8.3)	1.42 (1.05-1.94)	0 (0)	0 (0)	-
Sepsis	166 (10.0)	37 (4.7)	0.44 (0.31-0.64)	0 (0)	0 (0)	-
Cough	1813 (76.3)	1343 (95.2)	6.21 (4.77-8.08)	147 (93.6)	37 (92.5)	0.83 (0.21-3.20)
Shortness of breath	643 (49.3)	531 (61.6)	1.64 (1.38-1.96)	17 (11.2)	9 (28.1)	3.08 (1.22-7.74)
Fever (history)	1044 (53.4)	503 (45.9)	0.74 (0.63-0.86)	127 (81.9)	26 (76.4)	0.71 (0.29-1.74)
Fever ($\geq 38^{\circ}\text{C}$)	1718 (76.8)	847 (68.8)	0.66 (0.57-0.77)	19 (38.7)	4 (80.0)	6.31 (0.65-60.8)
Wheeze	669 (32.0)	527 (45.0)	1.73 (1.49-2.01)	2 (1.5)	3 (10)	6.94 (1.10-43.5)
Runny nose	856 (44.1)	590 (58.0)	1.75 (1.50-2.04)	2 (5.8)	2 (66.6)	32.0 (1.95-522.7)
Lower chest in-drawing	717 (41.5)	525 (63.6)	2.46 (2.07-2.91)	0 (0)	1 (50)	-
Pre-existing condition ^a	453 (18.1)	190 (7.9)	0.67 (0.56-0.80)	6 (4.0)	0 (0)	-
Children (6 m to <2 y)						
Cough	3170 (93.5)	1066 (96.5)	1.92 (1.35-2.74)	656 (91.2)	140 (90.3)	0.89 (0.49-1.62)
Shortness of breath	1483 (57.9)	565 (65.7)	1.39 (1.18-1.63)	92 (13.8)	27 (20.3)	1.58 (0.98-2.55)
Fever (history)	1858 (65.6)	597 (61.7)	0.84 (0.72-0.98)	583 (82.3)	126 (82.3)	1.00 (0.63-1.58)
Fever ($\geq 38^{\circ}\text{C}$)	2188 (71.6)	691 (69.3)	0.89 (0.76-1.04)	162 (54.9)	37 (77.0)	2.76 (1.35-5.62)
Wheeze	1102 (38.7)	384 (41.1)	1.10 (0.94-1.28)	38 (6.6)	14 (10.6)	1.67 (0.87-3.18)
Sore throat	629 (27.6)	218 (32.2)	1.24 (1.03-1.49)	101 (15.7)	21 (16.9)	1.09 (0.65-1.82)
Runny nose	1167 (49.4)	472 (61.3)	1.61 (1.36-1.90)	22 (13.9)	3 (21.4)	1.68 (0.43-6.52)
Lower chest in-drawing	904 (42.4)	343 (56.4)	1.75 (1.46-2.10)	6 (9.0)	3 (30.0)	4.28 (0.87-21.0)
Pre-existing condition ^a	590 (17.0)	183 (9.5)	0.93 (0.77-1.11)	17 (2.6)	6 (4.8)	1.86 (0.72-4.83)
Children (2 to <5 y)						
Cough	1250 (92.8)	172 (93.4)	1.10 (0.59-2.04)	542 (95.0)	86 (96.6)	1.48 (0.44-4.97)
Shortness of breath	586 (54.3)	90 (54.2)	0.99 (0.71-1.38)	57 (12.0)	14 (19.4)	1.75 (0.92-3.35)
Fever (history)	736 (64.7)	98 (60.4)	0.83 (0.59-1.16)	459 (81.2)	77 (83.7)	1.18 (0.65-2.14)
Fever ($\geq 38^{\circ}\text{C}$)	940 (75.5)	121 (71.6)	0.81 (0.57-1.17)	182 (70.5)	36 (85.7)	2.50 (1.01-6.19)
Wheeze	386 (34.0)	60 (36.5)	1.11 (0.79-1.56)	33 (7.8)	10 (14.0)	1.92 (0.90-4.09)
Sore throat	303 (31.8)	43 (34.9)	1.15 (0.77-1.70)	123 (27.1)	25 (39.6)	1.76 (1.02-3.04)
Runny nose	414 (48.3)	60 (50.8)	1.10 (0.75-1.62)	16 (14.2)	2 (28.5)	2.40 (0.42-13.4)
Lower chest in-drawing	277 (36.8)	47 (45.6)	1.43 (0.95-2.17)	8 (13.7)	0 (0)	-
Pre-existing condition ^a	305 (22.3)	33 (9.5)	0.74 (0.50-1.10)	23 (5.0)	3 (4.7)	0.93 (0.27-3.20)
Children (5 to <18 y)						
Cough	929 (86.7)	45 (91.8)	1.71 (0.60-4.85)	693 (96.1)	16 (84.2)	0.21 (0.05-0.78)
Shortness of breath	471 (44.3)	24 (48.9)	1.20 (0.67-2.13)	87 (17.1)	4 (30.7)	2.14 (0.64-7.10)
Fever (history)	600 (66.0)	21 (45.6)	0.43 (0.23-0.78)	635 (85.4)	17 (89.4)	1.44 (0.32-6.34)
Fever ($\geq 38^{\circ}\text{C}$)	669 (69.6)	27 (62.7)	0.73 (0.39-1.38)	237 (77.2)	4 (100.0)	-
Wheeze	178 (18.9)	9 (19.5)	1.04 (0.49-2.19)	30 (6.9)	1 (8.3)	1.20 (0.15-9.68)
Sore throat	350 (37.6)	8 (23.5)	0.50 (0.22-1.13)	218 (48.0)	2 (18.1)	0.24 (0.05-1.12)
Runny nose	197 (36.4)	15 (57.6)	2.38 (1.07-5.28)	21 (16.6)	0 (0)	-
Lower chest in-drawing	95 (22.8)	13 (52.0)	3.66 (1.61-8.28)	0 (0)	1 (100)	-
Pre-existing condition ^a	158 (14.6)	13 (8.6)	2.10 (1.08-4.04)	21 (4.6)	1 (9.0)	2.06 (0.25-16.8)
Adults (18 to <65 y)						
Cough	2326 (92.3)	71 (95.9)	1.95 (0.60-6.26)	1746 (96.2)	64 (94.1)	0.63 (0.22-1.78)

(Continues)

TABLE 4 (Continued)

	Inpatient surveillance			Outpatient surveillance		
	RSV negative n (%)	RSV positive n (%)	Univariate Odds ratio (95% CI)	RSV negative n (%)	RSV positive n (%)	Univariate Odds ratio (95% CI)
Shortness of breath	1351 (53.8)	39 (54.1)	1.01 (0.63-1.62)	572 (50.6)	21 (41.1)	0.68 (0.38-1.20)
Fever (history)	1493 (84.4)	43 (79.6)	0.72 (0.36-1.41)	1592 (88.8)	53 (80.3)	0.51 (0.27-0.95)
Fever ($\geq 38^{\circ}\text{C}$)	2051 (94.3)	47 (85.4)	0.35 (0.16-0.76)	353 (83.2)	20 (83.3)	1.00 (0.33-3.03)
Wheeze	432 (17.8)	9 (12.5)	0.65 (0.32-1.33)	184 (22.8)	7 (16.6)	0.67 (0.29-1.54)
Sore throat	799 (41.7)	20 (35.0)	0.75 (0.43-1.31)	387 (61.4)	17 (48.5)	0.59 (0.29-1.17)
Runny nose	388 (40.6)	10 (52.6)	1.62 (0.65-4.02)	43 (29.0)	2 (28.5)	0.97 (0.18-5.22)
Lower chest in-drawing	70 (12.1)	2 (28.5)	2.90 (0.55-15.2)	0 (0)	1 (16.6)	-
Pregnant	148 (9.0)	1 (2.3)	0.23 (0.03-1.75)	12 (2.5)	2 (8.0)	3.34 (0.70-15.8)
Pre-existing condition ^b	860 (33.7)	31 (41.8)	1.41 (0.88-2.25)	61 (9.5)	3 (8.3)	0.86 (0.25-2.89)
Older adults (65+ y)						
Cough	1065 (92.1)	51 (92.7)	1.08 (0.38-3.08)	359 (97.8)	17 (94.4)	0.37 (0.04-3.20)
Shortness of breath	763 (66.1)	39 (70.9)	1.24 (0.68-2.25)	146 (74.4)	9 (75.0)	1.02 (0.26-3.94)
Fever (history)	423 (62.2)	24 (58.5)	0.85 (0.45-1.62)	308 (94.4)	16 (100)	-
Fever ($\geq 38^{\circ}\text{C}$)	896 (83.8)	36 (75.0)	0.57 (0.29-1.13)	34 (82.9)	0 (0)	-
Wheeze	298 (27.2)	22 (40.0)	1.78 (1.02-3.10)	54 (47.7)	2 (40.0)	0.72 (0.11-4.52)
Sore throat	242 (29.9)	10 (24.3)	0.75 (0.36-1.56)	35 (58.3)	1 (33.3)	0.35 (0.03-4.15)
Runny nose	107 (38.6)	7 (36.8)	0.92 (0.35-2.42)	7 (36.8)	0 (0)	-
Lower chest in-drawing	62 (19.8)	6 (30.0)	1.72 (0.63-4.67)	0 (0)	0 (0)	-
Pre-existing condition ^b	762 (64.8)	37 (67.2)	1.11 (0.62-1.98)	21 (31.8)	1 (33.3)	1.07 (0.09-12.4)

^aPre-existing condition includes prematurity, chronic respiratory disease including asthma, malnutrition, or immunodeficiency.

^bPre-existing condition includes respiratory disease, diabetes, heart disease, or immunodeficiency.

Surveillance confirmed the high burden of RSV in children <2 years, especially in infants <6 months.^{7,18-20} RSV commonly manifests clinically in infants with bronchiolitis.²¹⁻²³ Wheeze has been one of the clinical end points of interest to evaluate vaccine efficacy trials.²⁴ From a surveillance case definition perspective, including wheeze as a criteria reduces its sensitivity in children.²⁵ Apnea, though it lacked sensitivity, was a significant clinical predictor for severe RSV infection requiring hospitalization in infants <6 months.^{22,26-28} The reason for sepsis to be significantly less common amongst RSV-positive hospitalized young infants in this study in contrast to other studies^{29,30} is unclear.

The RSV surveillance case definition is not intended to modify or replace the SARI or ILI case definition for influenza surveillance. Countries reported challenges in the adoption of the extended SARI case definition in the early stages of the RSV surveillance which were resolved through training. In practice, the physician or nurse in a sentinel hospital engaged in both RSV and influenza surveillance, screened patients with acute onset cough or shortness of breath, and collected an appropriate respiratory specimen. Information on the presence or absence of fever was recorded in the specimen requisition form and sent to the laboratory along with the respiratory specimen. At the laboratory, all the specimens were tested for RSV, whereas those specimens from patients with fever were additionally tested for influenza. Moreover, the results

for influenza were reported to FluNet only for those patients with fever. Notwithstanding the additional burden of reporting, this ensured that the RSV surveillance did not disturb the influenza surveillance system but complemented it by targeting a very young age-group that is important, yet often underrepresented in influenza surveillance.

The WHO RSV surveillance pilot had several limitations, and its early findings need to be interpreted with some caveats. Generalization of the findings should be made with caution. First, the number, type, and selection of sentinel sites varied across countries and were generally not designed to be nationally representative or comparable in terms of the clinical severity of patients included. Second, the strategy for sampling patients for testing varied across sentinel sites. This would need to be accounted for when estimating disease burden from surveillance data but is of no consequence for this analysis. Third, Brazil faced a shortfall of extended SARI cases and had to bridge the gap with patients sourced from SARI surveillance. However, with over 20 000 patients from all countries pooled together, the bias in evaluating the performance of fever as a criterion for detecting RSV would be small. Fourth, the PPV is likely to be higher during the RSV season, but it was beyond the scope of this analysis to robustly determine country-specific seasonality patterns from data that covered just 2 years.

TABLE 5 Performance of SARI and ILI case definitions with reference to extended SARI (inpatient surveillance) and ARI (outpatient surveillance), 2017-18

	Inpatient surveillance				Outpatient surveillance			
	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	AUC	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	AUC
Young infants (0 to <6 m)	Percent positivity – 36.9%				Percent positivity – 15.8%			
SARI (inpatient)/ILI (outpatient)	71% (69-73)	20% (18 –21)	34% (32-36)	0.31	71% (51-86)	15% (10-22)	13% (8-20)	0.43
Apnea	8.3% (6-10)	93% (92-95)	42% (34-49)	0.51	–	–	–	–
Sepsis	4.7% (3-6)	89% (88-91)	18% (13-24)	0.47	–	–	–	–
Ex-SARI/ARI + wheeze	36% (33-38)	73% (71-74)	44% (41-46)	0.47	0% (2-12)	98% (95-99)	–	0.49
Children (6 m to <2 y)	Percent positivity – 24.7%				Percent positivity – 16.1%			
SARI (inpatient)/ILI (outpatient)	82% (80-84)	16% (15-17)	24% (23-26)	0.32	83% (76-89)	11% (8-13)	15% (12-18)	0.47
Ex-SARI/ARI + wheeze	33% (31-36)	68% (66-69)	25% (23-28)	0.44	1.6% (0.2-6)	97% (96-98)	12% (2-39)	0.49
Children (2 to <5 y)	Percent positivity – 12.0%				Percent positivity –12.2%			
SARI (inpatient)/ILI (outpatient)	80% (74-85)	16% (14-18)	11% (9-13)	0.29	92% (82-97)	9.9% (7-13)	12% (9-15)	0.51
Ex-SARI/ARI + wheeze	32% (25-39)	71% (69-74)	13% (10-17)	0.44	0% (0-6)	97% (95-98)	–	0.48
Children (5 to <18 y)	Percent positivity – 4.3%				Percent positivity – 2.3%			
SARI (inpatient)/ILI (outpatient)	77% (63-87)	18% (15-20)	4% (2-5)	0.21	81% (48-97)	8.3% (6-11)	2% (1-4)	0.45
Ex-SARI/ARI + wheeze	18% (9-32)	83% (81-85)	4% (2-9)	0.44	0% (0-28)	99% (98-100)	–	0.49
Adults (18 to <65 y)	Percent positivity – 2.8%				Percent positivity – 5.3%			
SARI (inpatient)/ILI (outpatient)	89% (79-94)	6.6% (5-7)	2% (2-3)	0.47	86% (70-95)	16% (13-19)	5% (3-7)	0.51
Ex-SARI/ARI + wheeze	12% (6-22)	83% (81-84)	2% (0.9-4)	0.47	2.7% (0.1-14)	98% (97-99)	9% (0.4-42)	0.50
Older adults (65+ y)	Percent positivity – 4.4%				Percent positivity – 4.3%			
SARI (inpatient)/ILI (outpatient)	78% (64-87)	15% (13-17)	4% (3-5)	0.46	66% (9-99)	27% (17-39)	4% (0.6-14)	0.46
Ex-SARI/ARI + wheeze	40% (27-54)	74% (72-77)	6% (4-10)	0.57	0% (0-70)	98% (91-99)	–	0.49

Abbreviations: ARI, acute respiratory infection; AUC, area under curve; CI, confidence interval; Ex-SARI, extended severe acute respiratory infection; ILI, influenza-like illness; PPV, positive predictive value; SARI, severe acute respiratory infection.

There were several factors that could cause potential bias in the study. The clinical data were collected from patients or caregivers or physician records and could be subject to recall or measurement bias. It was beyond the scope of this analysis to evaluate the influence of recall of symptoms based on the interval between the onset of symptoms and when patients presented at the hospital or clinic. On the other hand, recall bias is not expected to be related to the RSV infection status. The health infrastructure, and healthcare availability, affordability and accessibility varied across different country contexts. The health seeking behavior of populations is likely to vary across different cultural contexts. The hospital admission practices are likely to vary across different settings as indicated by the heterogeneity in the severity of illness of patients screened for RSV also varied across different sites. It is beyond the scope, and not the purpose, of the RSV or any routine national disease surveillance system to collect information on these variables which are better studied in specialized research settings.

In conclusion, we found that pilot countries with existing influenza surveillance were able to build on RSV surveillance on top of their influenza surveillance program with marginal incremental costs and effort. Countries did not report any significant adverse impact on influenza surveillance. The inclusion of fever as a criterion substantially reduces the sensitivity of a case definition to detect RSV infection in young children, where the burden of RSV is the highest. WHO should continue to closely monitor for adverse impact, if any, on influenza surveillance in different settings.

ACKNOWLEDGEMENTS

The WHO global RSV surveillance pilot project was supported by an award made to the World Health Organization by the Bill and Melinda Gates Foundation (grant no. OPP1127419). The authors would like to thank all the national and international experts who participated in the informal consultations in March 2015, February

2016, and June 2016 that led to the development of the WHO RSV surveillance strategy, and in the project review meetings held in December 2017 and October 2018. We are grateful to the National Influenza Centres, Public Health Laboratories and the Ministries of Health of the participating countries for piloting the RSV surveillance strategy. We thank the Respiratory Viruses Branch, Division of Viral Diseases, CDC, Atlanta; the Public Health England at Colindale; and the National Institute of Communicable Diseases, Johannesburg for providing support as RSV reference laboratories for this project. We thank colleagues in the Global Influenza Programme, Influenza Preparedness and Response, Dept. of Infectious Hazards Management of the WHO Health Emergencies Programme for supporting this work.

ORCID

Siddhivinayak Hirve  <https://orcid.org/0000-0002-9651-7789>

REFERENCES

- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017;390(10098):946-958.
- PATH The global respiratory syncytial virus burden - a summary of the latest estimates. 2018.
- PATH. RSV vaccine and mAb snapshot. 2018. <https://vaccineresources.org/details.php?i=1562>. Accessed October 16, 2018.
- Falsey AR. Respiratory syncytial virus infection in adults. *Semin Respir Crit Care Med*. 2007;28(2):171-181.
- Falsey AR. Respiratory syncytial virus infection in elderly and high-risk adults. *Exp Lung Res*. 2005;31(Suppl 1):77.
- Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med*. 2009;360(6):588-598.
- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet*. 2017;390(10098):946-958.
- Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization Meeting held on 23-24 March 2015. *Vaccine*. 2016;34(2):190-197.
- Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. *Vaccine*. 2017;8-10. <https://doi.org/10.1016/j.vaccine.2016.10.090>
- Breiman RF, Van Beneden CA, Farnon EC. Surveillance for respiratory infections in low- and middle-income countries: experience from the Centers for Disease Control and Prevention's Global Disease Detection International Emerging Infections Program. *J Infect Dis*. 2013;208(Suppl 3):S167-S172.
- Haynes AK, Manangan AP, Iwane MK, et al. Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers. *J Infect Dis*. 2013;208(Suppl 3):S246-S254.
- Rha B, Dahl RM, Moyes J, et al. Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness-South Africa, 2009-2014. *J Pediatric Infect Dis Soc*. 2019;8(4):325-333.
- Saha S, Pandey BG, Choudekar A, et al. Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of northern India. *J Glob Health*. 2015;5(2):010419.
- Nyawanda BO, Mott JA, Njuguna HN, et al. Evaluation of case definitions to detect respiratory syncytial virus infection in hospitalized children below 5 years in Rural Western Kenya, 2009-2013. *BMC Infect Dis*. 2016;16:218.
- World Health Organization. WHO strategy to pilot Global Respiratory Syncytial Virus surveillance based on the Global Influenza Surveillance and Response System (GISRS). 2017.
- World Health Organization Global Epidemiological Surveillance Standards for Influenza. 2014. http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf. Accessed September 29, 2019.
- World Health Organization. G.I.S.N. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011.
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet*. 2010;375(9725):1545-1555.
- Nair H, Simões EAF, Rudan I, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. *Lancet*. 2013;381(9875):1380-1390.
- Schanzer DL, Saboui M, Lee L, Nwosu A, Bancej C. Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003-2014. *Influenza Other Respir Viruses*. 2018;12(1):113-121.
- Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. *Eur J Pediatr*. 2018;177(6):913-920.
- Laham FR, et al. Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis. *Pediatr Infect Dis J*. 2017;36(8):808-810.
- Leung AK, Kellner JD, Davies HD. Respiratory syncytial virus bronchiolitis. *J Natl Med Assoc*. 2005;97(12):1708-1713.
- Riddell CA, Bhat N, Bont LJ, et al. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: a sample size analysis. *Vaccine*. 2018;36(52):8100-8109.
- Omer SB, Bednarczyk R, Kazi M, et al. Assessment and validation of syndromic case definitions for respiratory syncytial virus testing in a low resource population. *Pediatr Infect Dis J*. 2019;38(3):e57-e59.
- Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. *J Pediatr*. 2009;155(5):728-733.
- Jafri HS, et al. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. *Pediatr Infect Dis J*. 2013;32(4):335-340.
- Sabogal C, Auais A, Napchan G, et al. Effect of respiratory syncytial virus on apnea in weanling rats. *Pediatr Res*. 2005;57(6):819-825.
- Khuri-Bulos N, Lawrence L, Piya B, et al. Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan. *BMJ Open*. 2018;8(5):e021898.

30. Moyes J, et al. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010–2011. *J Infect Dis*. 2013;208(Suppl 3):S217–S226.

How to cite this article: Hirve S, Crawford N, Palekar R, Zhang W; on behalf of the WHO RSV surveillance Group. Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot. *Influenza Other Respi Viruses*. 2020;14:647–657. <https://doi.org/10.1111/irv.12688>

APPENDIX A

WHO RSV SURVEILLANCE GROUP

Christina Bancej¹, Ian Barr², Elsa Baumeister³, Shobha Broor⁴, Alyeksandr Burmaa⁵, Harry Campbell⁶, Braulia Caetano⁷, Mandeep Chadha⁸, Malinee Chittaganpitch⁹, Daouda Coulibaly¹⁰, Badarch Darmaa¹¹, Joanna Ellis¹², Manal Fahim¹³, Rodrigo Fasce¹⁴, Kadjo Herve¹⁵, Sandra Jackson¹⁶, Maria Pisareva¹⁷, Jocelyn Moyes¹⁸, Amel Naguib¹⁹, Harish Nair⁶, Richard Pebody²⁰, Varsha Potdar⁸, Soatiana Rajatonirina²¹, Marilda Siqueira⁷, Peter G. Smith²², Elizaveta Smorodintseva²³, Viviana Sotomayor²⁴, Florette Treurnicht¹⁸, Almiro Tivane²⁵, Marietjie Venter²⁶, Niteen Wairagkar²⁷, Maria Zambon¹²

¹Centre for Immunization and Respiratory Infections, Public Health Agency of Canada, Ottawa, Canada

²Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

³Departamento Virología, INEI-ANLIS “Carlos G Malbrán”, Buenos Aires, Argentina

⁴Medicine and Health Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram, India

⁵National Influenza Surveillance Division, National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia

⁶Usher Institute of Population Health Research and Informatics, University of Edinburgh, Edinburgh, United Kingdom

⁷Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil

⁸National Institute of Virology, Indian Council of Medical Research, Pune, India

⁹Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand

¹⁰Epidemiological Surveillance and Research, Institut National de l'Hygiène Publique, Abidjan, Côte d'Ivoire

¹¹Virology Laboratory, National Center for Communicable Diseases, Ulaanbaatar, Mongolia

¹²Virus Reference Department, Public Health England, London, United Kingdom

¹³Dept of Surveillance and Epidemiology, Ministry of Health and Population, Cairo, Egypt

¹⁴Sub-department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile

¹⁵Department of Epidemic Viruses, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire

¹⁶Global Influenza Program, World Health Organization, Geneva, Switzerland

¹⁷Laboratory of Molecular Virology, Smorodintsev Research Institute of Influenza, St. Petersburg, Russian Federation

¹⁸Center for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa

¹⁹Central Public Health Laboratory, Ministry of Health, Cairo, Egypt

²⁰Flu Surveillance, Public Health England, London, United Kingdom

²¹African Region Office, World Health Organization, Brazzaville, Republic of Congo

²²MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom

²³Laboratory for studying risk factors of Influenza and ARVI, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation

²⁴Division de Planificación Sanitaria, Ministerio de Salud Chile, Santiago, Chile

²⁵Laboratório de Isolamento Viral, Instituto Nacional de Saúde, Maputo, Mozambique

²⁶Center for Viral Zoonosis, Department of Medical Virology, University of Pretoria, South Africa

²⁷Bill and Melinda Gates Foundation, Seattle, United States